[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100645499":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":29,"centralContacts":33,"locations":11,"responsibleParty":41,"collaborators":11,"id":43,"slug":44,"hasResults":45,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":11,"eligibilityCriteria":49,"healthyVolunteers":50,"sex":51,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":11,"studyType":57,"phases":58,"briefSummary":60,"conditions":61,"keywords":63,"overallStatus":73,"whyStopped":11,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":11},{"fullName":5,"class":6},"Celgene","INDUSTRY",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Cohort 1","EXPERIMENTAL",null,[13,14],"Drug: BMS-986368","Other: BMS-986368-matching Placebo",{"label":16,"type":10,"description":11,"interventionNames":17},"Cohort 2",[13,14],[19,24],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":11},"DRUG","BMS-986368","Specified dose on specified days",[9,16],{"type":25,"name":26,"description":27,"armGroupLabels":28,"otherNames":11},"OTHER","BMS-986368-matching Placebo","Specified dose of specified days",[9,16],[30],{"name":31,"affiliation":31,"role":32},"Bristol-Myers Squibb","STUDY_DIRECTOR",[34,39],{"name":35,"role":36,"phone":37,"phoneExt":11,"email":38},"BMS Clinical Trials Contact Center www.BMSClinicalTrials.com","CONTACT","855-907-3286","Clinical.Trials@bms.com",{"name":40,"role":36,"phone":11,"phoneExt":11,"email":11},"First line of the email MUST contain NCT # and Site #.",{"type":42,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100645499","phase-1-a-study-to-evaluate-the-blood-levels-safety-and-tolerability-of-bms-986368-in-healthy-chinese-participants-100645499",false,"NCT07700329","A Study to Evaluate the Blood Levels, Safety, and Tolerability of BMS-986368 in Healthy Chinese Participants","A Phase 1, Double-Blinded, Randomized, Placebo-Controlled, Two Parallel Cohort Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of BMS-986368 in Healthy Chinese Participants","Inclusion Criteria:\n\n* Participants must be healthy male or non-pregnant and non-nursing female (as assigned at birth).\n* Participants must be of Chinese ethnicity (both biological parents should be ethnically Chinese).\n* Participants must have BMI of 18.0 kg\u002Fm2 to 28.0 kg\u002Fm2, inclusive and body weight of ≥ 50 kg.\n\nExclusion Criteria:\n\n* Participants must not have personal or first-degree family history of clinically significant psychiatric disorder, including, but not limited to, schizophrenia, psychosis, bipolar disorder, major depressive disorder, generalized anxiety disorder, obsessive-compulsive disorder, and post-traumatic stress disorder. Participants with a history of anxiety may be enrolled at the discretion of the investigator.\n* Participants must not have an active or prior history of stroke, chronic seizures, or major neurological disorders or has first-degree family relative who was diagnosed with these disorders below the age of 65 years.\n* Other protocol-defined Inclusion\u002FExclusion criteria apply.",true,"ALL","18 Years","55 Years",{"count":55,"type":56},16,"ESTIMATED","INTERVENTIONAL",[59],"PHASE1","The purpose of the study is to evaluate the drug levels, safety and tolerability of BMS-986368 in healthy Chinese participants",[62],"Healthy Volunteers",[21,64,65,66,67,68,69,70,71,72],"CC-97489","Healthy volunteers","Healthy Chinese participants","Pharmacokinetics","Safety","Tolerability","FAAH inhibitor","MAGL inhibitor","Phase 1","NOT_YET_RECRUITING","2026-07-09",{"date":76,"type":77},"2026-07-14","ACTUAL",{"date":79,"type":56},"2027-01-05",{"date":81,"type":56},"2027-02-23",{"name":5,"class":6}]